AbbVie Inc. (ABBV) 주식 — 좋은 사업일까?

AbbVie Inc. (ABBV) 주식 — 좋은 사업일까? — InspectStocks

Just reported

Q3 2026 results

From AbbVie's results release of 2026년 10월 30일; its quarterly report has since been filed.

Revenue
Actual
US$17.4B
+10% y/y
+2.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$6.27B
+229% y/y
-2.6% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

어떻게 돈을 버는가

Sales of medicines and therapies100%

매출 비중은 fiscal year 2025, high confidence 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.

3개 더 보기

Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.

누가 사는가5

Wholesalers and distributors buy medicines for resale to pharmacies, hospitals and other healthcare providers.
Government agencies and public health programs buy medicines or set coverage and reimbursement terms.
Health insurers and pharmacy benefit managers influence which medicines patients can access and the prices or rebates paid.

2개 더 보기

Hospitals, health facilities, specialty pharmacies and independent pharmacies buy medicines for use or dispensing to patients.
Physicians and other licensed healthcare providers prescribe AbbVie's prescription medicines and can buy some aesthetic products and devices directly.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1AbbVie relies on large wholesale distributors to move its medicines, especially in the United States.
2Some medicines or manufacturing components depend on a limited number of suppliers, and in some cases a single supply source.
3Revenue depends on patents and regulatory exclusivity; Humira already faces biosimilar competition.
4Pricing and patient access depend partly on government reimbursement rules, insurers and pharmacy benefit managers.
5The business depends on discovering, testing and obtaining regulatory approval for new medicines, including products developed with collaborators.

잘못될 수 있는 일

1Patent expirations and biosimilar or generic competition can reduce sales. Humira's sales continued to fall amid biosimilar competition in the six months ended June 30, 2026.
2Government price controls, reimbursement limits and pressure from insurers and pharmacy benefit managers can reduce the prices AbbVie receives for its medicines.
3Research and development may not produce medicines that pass clinical trials and regulatory review or attract enough use after approval, leaving gaps as existing products lose exclusivity.

전체 재무제표 보기 →

AbbVie Inc. 소개

AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.

본사: North Chicago, Illinois, United States
설립: 2012 (incorporated; began independent public trading in 2013)
임직원 수: Approximately 57,000 (December 31, 2025, high confidence)
상장 시장: New York Stock Exchange
회계연도 종료: December 31

AbbVie Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported

Q3 2026 results

From AbbVie's results release of 2026년 10월 30일; its quarterly report has since been filed.

Revenue
Actual
US$17.4B
+10% y/y
+2.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$6.27B
+229% y/y
-2.6% q/q
Guided
—
No guide given

The full earnings report →

Keep exploring

The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises